Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2006-05-16
2006-05-16
Rao, Manjunath N. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S004000, C435S006120, C435S018000, C435S069100, C435S183000, C435S195000, C536S023200, C536S023500
Reexamination Certificate
active
07045329
ABSTRACT:
The enzyme Lp-PLA2in purified form, an isolated nucleic acid molecule encoding Lp-PLA2, the use of an inhibitor of the enzyme Lp-PLA2 in therapy and a method of screening compounds to identify those compounds which inhibit the enzyme.
REFERENCES:
patent: 5527698 (1996-06-01), Knopf et al.
patent: 5532152 (1996-07-01), Cousens et al.
patent: 5641669 (1997-06-01), Cousens et al.
patent: 5840839 (1998-11-01), Wang et al.
patent: 5968818 (1999-10-01), Gloger et al.
patent: 5981252 (1999-11-01), MacPhee et al.
patent: 0359425 (1988-08-01), None
patent: 0509719 (1992-10-01), None
patent: WO89/09818 (1989-10-01), None
patent: WO95/00649 (1995-01-01), None
Steinbrecher et al. (J. Lipid Res., 1989, vol. 30(3) :305-315).
Stremler KE et al. (J. Biol. Chem., 1989, vol. 264(10):5331-5334).
Kohler G, et al., Nature 256:495-497 (1975).
Sevier Ed, et al., Clinical Chem. 27:1797-1806 (1981).
Chandrakumar Ns, et al., “Stereospecific Synthesis of Ehter Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2-deoxyglycerophosphoryl cholines,” J. Org. Chem., 1197-1202 (1983).
Ponpipom MM, et al., “Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives,” Chem. Phys. Lipids;35:29-37 (1984).
Stafforini D, et al., “Human plasma platelet-activating factor acetylhydrolase,” J. Biol. Chem. 262(9): 4224-4230 (1987).
Stafforini D, et al. “Human macrophages secrete plate-activating factor acetylhydrolase,” J. Biol. Chem 265(17):9682-9687 (1990).
Langlais J. et al., Platelet-activating factor acetyl-hydrolase in human semen: a novel decapacitation factor? Biol. of Reprod. 44 (Suppl. 1):94 (1991).
San H, et al. “Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Therapy,” Human Gene Therapy: 781-798 (1993).
Kim Ut, et al. “Synthesis of Phospholipid Headgroups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes,” J. Chem. Soc. Commun.: 70-71 (1993).
Christofferson R, et al. “Ribozymes as Human Therapeutic Agents,” J. of Medicinal Chem.: 2023-2037 (1994).
Stull R, et al., “Antigene, Ribozyme, and Aptomer Nucleic Acid Drugs: Progress and Prospects,” Pharm. Res. 1995.
Chandrakumar NS, et al., “Stereospecific Synthesis of Ether Phospholipids. Preparation of a-Alkyl-2-(acylamino)-2-deoxyglycerophosphoryl cholines,”J. Org. Chem., 1197-1202 (1983).
Ponpipom MM, et al., “Synthesis of Azide and Amide Analogs of Platelet-Activating Factors and Related Derivatives,”Chem. Phys. Lipids. 35:29-37 (1984).
Stafforini D, et al., “Human plasma platelet-activating factor acetylhydrolase,”J. Biol. Chem. 262(9):4223-4230 (1987).
Stafforini D, et al. “Human macrophages secrete plate-activating factor acetylhydrolase,”J. Biol. Chem. 265(17):9682-9687 (1990).
Langlais J., et al., Platelet-activating factor acetyl-hydrolase in human semen: a novel decapacitation factor?Biol. of Reprod. 44 (Suppl.1):94 (1991).
San H., et al. “Safety and Short Term Toxicity of a Novel and Cationic Formulation for Human Gene Theraphy,”Human Gene Therapy: 781-798 (1993).
Kim UT, et al. “Synthesis of Phospholipid Headgroups via Nucleophilic Ring Opening of 1.3.2-Dioxaphospholanes,”J. Chem. Soc. Chem. Commun.: 70-71 (1993).
U.S. Appl. No. 10/415,682, Campbell et al., dated May 2003.
U.S. Appl. No. 11/141,554, MacPhee, et al., dated May 2005.
Christofferson R, et al. “Ribozymes as Human Therapeutic Agents,”J. of Medicinal Chem.: 2023-2047 (1994).
Stull R, et al., “Antigene, Ribozyme, and Sptomer Nucleic Acid Drugs: Progress and Prospects,”Pharm. Res. 12(4):465-483(1995).
Steinbrecher et al., “Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase,”J. Lipid Res., 30(3):305-315 (1989).
Stremier K E, et al., “An Oxidized Derivative of Phosphatidylcholine is a Substrate for the Platelet-activating Factor Aceylhydrolase from Human Plasma,”J. Biol. Chem., 264(10):5331-5334 (1989).
Sevier ED, et al., “Monoclonal Antibodies in Clinical Immunology,”Clinical Chem. 27:1797-1806 (1981).
Kohler G, et al.,Nature236:495-497 (1975).
Bell, Rachel, et al., “Systematic screening of the LDL-PLA2 gene for polymorphic variants and case-control polymorphic variants and case-control analysis in schizophrenia,”Biochemical and Biophysical Research Communications, 241(3): 630-635 (1997) XP002197530.
Yamada, Yoshiji, et al., “Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese Population”,Atherosclerosis, 150(1):209-216(2000) XP002197527.
Hiramoto, Maoto, et al., “A mutation in plasma platelet-activating factor acetylhydrolase (Val279fwdarwPhe) is a genetic risk factor for stroke.”Stroke, 28(12):2417-2420 (Dec. 12, 1997) XP002197528.
Kruse, Susanne, et al., “The Ilel98Thr and Ala379Val variants of plasmatic Paf-acetylhydrolase impair catalytical activities and are associated with atophy and asthma,”Am. Journal of Human Genetics, 66(5):1522-1530 (2000) XP002197529.
Tew, D. G., et al., “Purification, properties, sequencing and cloning of a lipo-protien-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins”,Arteriosclerosis Thrombosis and Vascular Biology, 16(4):591-599 (Apr. 1996).
Tjoelker, I.W., “Anti-inflammatory properties of a platelet-activating factor acetylhyrdrolase”,Nature, MacMillan Journals Ltd., London, 374(6):549-553 (Apr. 1995) XP002I09103.
Gloger Israel Simon
Hickey Deirdre Mary Bernadette
Lawrence Geoffrey Mark Prouse
MacPhee Colin Houston
Rice Simon Quentyn John
Gimmi Edward R.
Han William T.
Lockenour Andrea V.
Rao Manjunath N.
SmithKline Beecham plc
LandOfFree
Lipoprotein associated phospholipase A2, inhibitors thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lipoprotein associated phospholipase A2, inhibitors thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lipoprotein associated phospholipase A2, inhibitors thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3582884